Clinical Trials Search
Title |
Intervention | NCT ID | Sponsor | Status |
|---|---|---|---|---|
| New Assessment System in Measuring Symptom Distress in Cancer Patients | Interview, Quality-of-Life Assessment, Questionnaire Administration | NCT00505245 | M.D. Anderson Cancer Center | Recruiting |
| Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by... | Laboratory Biomarker Analysis, Nutritional Intervention, Placebo, Quality-of-Life Assessment, Questionnaire Administration | NCT03757949 | Southwest Oncology Group | Active, not recruiting |
| Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and... | Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo | NCT03578081 | Alliance for Clinical Trials in Oncology | Recruiting |
| Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2... | Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment | NCT03633331 | Alliance for Clinical Trials in Oncology | Active, not recruiting |
| Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil | Donepezil 5 mg, Placebo | NCT02822573 | Wake Forest University Health Sciences | Recruiting |
| Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Therapeutic Conventional Surgery | NCT00118040 | National Cancer Institute (NCI) | Active, not recruiting |
| Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk | Metformin, Placebo | NCT02028221 | University of Arizona | Active, not recruiting |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | Questionnaire Administration, Z-Endoxifen Hydrochloride, Placebo Administration | NCT03317405 | National Cancer Institute (NCI) | Active, not recruiting |
| Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-... | Denosumab, Salpingo-Oophorectomy | NCT03382574 | National Cancer Institute (NCI) | Recruiting |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast... | Endocrine therapy interruption | NCT02308085 | International Breast Cancer Study Group | Active, not recruiting |